Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US2183521028
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BF8JD9
CORT
Corcept Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Corcept Therapeutics Inc
ISIN
US2183521028
TICKER
CORT
MIC
XNAS
REUTERS
CORT.OQ
BLOOMBERG
CORT US
Di., 03.11.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of t...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 27.10.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the co...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 26.10.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company’s Phase 2 BELLA trial, whic...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 20.10.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Associati...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 23.09.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products f...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.07.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.07.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.06.2026       Corcept Therapeutics
US2183521028

NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. ...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and D...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 17.06.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed t...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 06.06.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of new data from its CATALYST and MOMENTUM trials at t...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lif...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Dr...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced two-year overall survival data from the Phase 2 DAZALS study of its pro...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026. Financial Results...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conf...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, in...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 21.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT during the class period listed are...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Corcept Therapeutics
US2183521028

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm urges investors who suffered significant losses between October 31, 2024, and...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) have opportunity to lead the securities fraud class action lawsuit....
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 20, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Corcept Therapeutics
US2183521028

CORT Investors with Losses Encouraged to Contact Firm Before April 21 DeadlineSAN FRANCISCO, April 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Corcept Therapeutics
US2183521028

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Corcept Therapeutics
US2183521028

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 DeadlineSAN FRANCISCO, April 17, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical Ap...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, in...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Corcept Therapeutics
US2183521028

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 21, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 202...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquir...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Corcept Therapeutics
US2183521028

SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm urges investors who suffered significant losses between October 31, 2024, and...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT)....
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT during the class period listed are...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, in...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Corcept Therapeutics
US2183521028

SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the critical April 21, 2026 lead plaintiff deadline in the pending securities class action. The firm urges investors who suffered significant losses between October 31, 2024, and...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Zur Nachricht
Corcept Therapeutics
Charts & Research Termsheets Terminal
Permalink